LX212

LX212 is a proprietary, bioerodible polymer implant containing voclosporin. It is designed to elute the active ingredient slowly and steadily to the surface of the eye. LX212 is small and is implanted using a minimally invasive procedure. The drug product is under development in collaboration with a research team at the Center for Biomaterials at Rutgers University. The polymer was selected from Rutgers' proprietary polymer library to which Lux Biosciences has an exclusive, worldwide license for ophthalmic use. The polymer erodes slowly while in the tissue, and its degradation products are resorbed by the body.

The product is currently in the preclinical stage of research, which has resulted in data supporting excellent tissue compatibility and drug release in the desired range, and with the desired profile over time. The implant will allow high and sustained local concentrations of the drug while producing very low systemic exposure. Importantly, as an implant lasting for many months, patient compliance is ensured. The high local concentrations and the long-term compliance may translate into enhanced efficacy and patient benefit.

Rutgers, The State University of New Jersey, and the Center for Biomaterials